1. Home
  2. Analysis
  3. Tobrex
  4. Intervertebral-disc-protrusion

Tobrex and Intervertebral disc protrusion - a phase IV clinical study of FDA data

Summary:

Intervertebral disc protrusion is reported as a side effect among people who take Tobrex (tobramycin), especially for people who are female, 30-39 old, also take Gabapentin, and have Sleep apnea syndrome.

The phase IV clinical study analyzes which people have Intervertebral disc protrusion when taking Tobrex. It is created by eHealthMe based on reports of 752 people who have side effects when taking Tobrex from the FDA, and is updated regularly.

What is Tobrex?

Tobrex has active ingredients of tobramycin. eHealthMe is studying from 762 Tobrex users. Check the latest studies of Tobrex.

What is Intervertebral disc protrusion?

Intervertebral disc protrusion (spinal disc protrusion) is found to be associated with 1,531 drugs and 1,305 conditions by eHealthMe. Check the latest studies of Intervertebral disc protrusion.

On Jul, 14, 2026

752 people reported to have side effects when taking Tobrex.
Among them, 15 people (1.99%) have Intervertebral disc protrusion.

Could Tobrex cause Intervertebral disc protrusion?

Among these 15 people:

What is the gender of people who have Intervertebral disc protrusion when taking Tobrex? *

  • female: 86.67 %
  • male: 13.33 %

What is the age of people who have Intervertebral disc protrusion when taking Tobrex? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 80 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 20 %

What are other drugs people take besides Tobrex? *

  1. Zyprexa: 13 people, 86.67%
  2. Oxycontin: 13 people, 86.67%
  3. Dalmane: 13 people, 86.67%
  4. Desoxyn: 13 people, 86.67%
  5. Dexamethasone: 13 people, 86.67%
  6. Celexa: 13 people, 86.67%
  7. Fenofibrate: 13 people, 86.67%
  8. Flonase: 13 people, 86.67%
  9. Carboplatin: 13 people, 86.67%
  10. Gabapentin: 13 people, 86.67%

What are other side effects people have besides Intervertebral disc protrusion? *

  1. Back Pain: 15 people, 100.00%
  2. Dyspnea (difficult or laboured breathing): 14 people, 93.33%
  3. Weight Increased: 13 people, 86.67%
  4. Implant Site Infection: 13 people, 86.67%
  5. High Blood Cholesterol: 13 people, 86.67%
  6. Hip Fracture: 13 people, 86.67%
  7. Hordeolum (small collection of pus (abscess) on the eyelid): 13 people, 86.67%
  8. Hot Flush (sudden feelings of heat): 13 people, 86.67%
  9. Human Papilloma Virus Test Positive: 13 people, 86.67%
  10. Hypoaesthesia (reduced sense of touch or sensation): 13 people, 86.67%

What are the existing conditions these people have? *

  1. Sleep Apnea Syndrome: 13 people, 86.67%
  2. Metastases To Bone (cancer spreads to bone): 6 people, 40.00%
  3. Bone Loss: 4 people, 26.67%
  4. Bone Density Decreased: 3 people, 20.00%
  5. Idiopathic Pulmonary Fibrosis (chronic lung disease): 2 people, 13.33%
  6. Pain: 1 person, 6.67%
  7. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tobrex and have Intervertebral disc protrusion?

- Check whether Intervertebral disc protrusion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tobrex:

Intervertebral disc protrusion treatments and more:

How severe was Intervertebral disc protrusion and when was it recovered:

Expand to all the drugs that have ingredients of tobramycin:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tobrex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Intervertebral disc protrusion:

Browse all the conditions that are associated with Intervertebral disc protrusion:

How the study uses the data?

The study uses data from the FDA. It is based on tobramycin (the active ingredients of Tobrex) and Tobrex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.